Discovering LINC00924: A Non-Protein Coding RNA Molecule with Potential as A Drug Target

Target Name: LINC00924

NCBI ID: G145820

LINC00924

Other Name(s): Long intergenic non-protein coding RNA 924, transcript variant 2 | Long intergenic non-protein coding RNA 924, transcript variant 1 | long intergenic non-protein coding RNA 924

Discovering LINC00924: A Non-Protein Coding RNA Molecule with Potential as A Drug Target

LINC00924 is a non-protein coding RNA (ncRNA) molecule located within intron 9 of the human genome. It is a transcribed gene that is not encoding any protein, but has been shown to play a role in regulating gene expression. LINC00924 is a potential drug target and has been investigated for its potential utility as a biomarker in various diseases, including cancer.

The discovery and characterization of LINC00924

LINC00924 was first identified in the human dataset using bioinformatics tools that were designed to identify transcribed genes that were not annotated as proteins. The gene was named based on its location within intron 9, as the \"924\" part of its name.

To further study the function of LINC00924, researchers used RNA sequencing (RNA-seq) to investigate its expression levels in various tissues and cell types. They found that LINC00924 was highly expressed in the brain, and that its expression was downregulated in various diseases, including cancer.

The potential utility of LINC00924 as a drug target

The potential utility of LINC00924 as a drug target is based on its ability to regulate gene expression and its expression levels, which are often disrupted in various diseases. LINC00924 has been shown to play a role in regulating the expression of genes involved in cell adhesion, migration and invasion, which are often disrupted in cancer.

Additionally, LINC00924 has also been shown to play a role in regulating the expression of genes involved in cell survival and angiogenesis, which are often disrupted in diseases such as cancer.

The potential clinical applications of LINC00924 as a drug target

The potential clinical applications of LINC00924 as a drug target are vast. LINC00924 has been shown to be downregulated in various diseases, including cancer, and therefore, targeting its expression levels could be a promising approach to treating these diseases.

One potential approach to using LINC00924 as a drug target is to use small molecules to either activate or inhibit its expression. This could involve using drugs that target specific RNA binding proteins that are known to interact with LINC00924, or using drugs that alter its stability or degradation.

Another potential approach to using LINC00924 as a drug target is to use RNA interference (RNAi) technology to knockdown its expression. This could involve using small interfering RNA (siRNA) to specifically target the mRNA of LINC00924, or using CRISPR/Cas9 technology to edit the RNA of LINC00924.

Finally, LINC00924 could also be used as a biomarker to diagnose diseases. Its expression levels can be used as a proxy for the overall health of a patient, and its levels may be affected by various diseases, including cancer.

Overall, LINC00924 is a promising drug target and has the potential to be used to treat a wide range of diseases. Further research is needed to fully understand its function and to develop effective therapies.

Protein Name: Long Intergenic Non-protein Coding RNA 924

The "LINC00924 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00924 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets